CDKN2A and neoplasm: P16 demonstrates its tumor suppressive activity through the inhibition of cyclin-dependent kinase CDK4 and CDK6 expression and limiting retinoblastoma protein phosphorylation during the G1/S cell cycle checkpoint [21].